pedsendo.org valid

Automatically discovered from public files. Ownership management is optional. Inclusion does not imply endorsement or publisher participation.

Manage this listing — optional · Visit publisher ↗

Claim my listing on Agent Web Map for pedsendo.org:
1. POST https://agentwebmap.com/v1/sites/pedsendo.org/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://pedsendo.org/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/pedsendo.org/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/pedsendo.org).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory. Ownership management is optional.

Pediatric Endocrine Society

Generated by All in One SEO v5.0.2.1, this is an llms.txt file, used by LLMs to index the site.

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T00:42:18.445Z. Cached copy · Source on pedsendo.org

# Pediatric Endocrine Society

> Generated by All in One SEO v5.0.2.1, this is an llms.txt file, used by LLMs to index the site.

Advancing Endocrine Health in Children and Adolescents

## Sitemaps

- [XML Sitemap](https://pedsendo.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [New Meds and Tech: FDA Alert for Medical Providers Regarding Necrolytic Migratory Erythema (NME) with Chronic Glucagon Use](https://pedsendo.org/new-meds-and-tech/new-meds-and-tech-fda-alert-for-medical-providers-regarding-necrolytic-migratory-erythema-nme-with-chronic-glucagon-use/): 5.5 Necrolytic Migratory Erythema Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with
- [New Meds and Tech: Tirosint-SOL](https://pedsendo.org/new-meds-and-tech/new-meds-and-tech-tirosint-sol/): Levothyroxine sodium oral solution (Tirosint-SOL) has now been approved by the FDA and is available for use in the US. Please click on the link below for details regarding the product and its dosing. This is for informational purposes only, and is not meant to be an endorsement of the product by PES.
- [New Meds and Tech: Vitamin D Preparations and Safety Issues](https://pedsendo.org/new-meds-and-tech/new-meds-and-tech-vitamin-d-preparations-and-safety-issues/): Vitamin D is a fat soluble vitamin that is essential for maintaining bone health and also has other potential health benefits. While some of these other health benefits are not yet well defined, vitamin D is important for achieving and maintain optimal bone density, prevention of rickets and osteomalacia. Because of this, vitamin D is
- [New Meds and Tech: Glucagon Preparations](https://pedsendo.org/new-meds-and-tech/new-meds-and-tech-glucagon-preparations/): The FDA has approved two new ready to use forms of glucagon and these have been introduced to the market: an intranasal powder (Baqsimi, Eli Lilly) and a stable liquid form without need for reconstitution (Gvoke, Xeris Pharmaceuticals). These innovative formulations provide the reliability of a ready-to-use glucagon preparation that can be administered quickly and
- [New Meds and Tech: Increlex](https://pedsendo.org/new-meds-and-tech/new-meds-and-tech-increlex/): In response to findings of a safety signal report that there is reasonable suspicion of a causal association between use of Increlex® and childhood neoplasia, including malignancy, changes have been made to the Prescribing Information (PI) and Patient Package Insert (PPI) of Increlex ® (Mecasermin, recombinant human insulin-like growth factor-1) manufactured by Ipsen pharmaceuticals.
- [New Meds and Tech: Newer Insulin Preparation - Faster Insulin Aspart (Fias
…

Related sites

Other listed sites in Marketing. See the whole category →

Help agents understand your site

Optionally manage your description, publish terms for agents, review file health, measured discovery requests, publisher clicks and score history. Confirm domain control in your browser using a fresh token in your llms.txt, DNS, meta tag or well-known file. No backlink is required.

Manage this listing → · Agent and API instructions

Machine-readable: GET /v1/resolve?q=pedsendo.org · GET /v1/domain/pedsendo.org · this page as Accept: application/json or text/markdown · MCP lookup_domain